The new guidelines for the use of monoclonal antibodies (MABs) published in neurodegenerative diseases, serve as exemplary clinical recommendations for clinics and care providers, to support the progress of the disease treatment of Alzheimer’s in Switzerland.
The Swiss Memory Clinics (SMC) Network, a group of specialized clinics in Switzerland that diagnose and treat patients with dementia, released new national guidelines on the use of anti-amyloid MABS such as Lecanemab and Donanemab-for the treatment of Alzheimer’s disease. Lecanemab is now also authorized by the European Commission under strict conditions.
Published in the number of 11 April 2025 of Neurodegenerative diseasesA karger journal, the paper represents a coordinated effort from the SMC network to guarantee a safe, effective and ethical implementation of these emerging therapies. As a clinical practical guide for clinicians and caregivers, it facilitates the implementation of emerging treatment options in the field of Alzheimer’s disease.
The paper outlines criteria for patient selection, biomarker confirmation, apoe -genotyping, aria monitoring via MRI and the infrastructure needed to support the security of safe treatment. It also emphasizes the importance of informed permission and recommends the establishment of a National Patient Register.
De richtlijnen komen voort uit interdisciplinaire discussies tussen clinici in het SMC-netwerk-neurologen, geriatrici, oudere psychiaters, neuropsychologen, neuroradiologen en patiëntenorganisaties, inclusief vertegenwoordigers van academische en niet-academische geheugenklinieken-Betweenheid tussen augustus 2023 en in de eerste country-specifieke framework voor integratie van MABS-in-Clinical cables in the integration of the Mabs Maks in the institution.
In a joint statement, the main authors have Dr. Med ANSGAR FELBECKER and Professor Giovanni B. Frisoni noted: “We have built up an expert group of specialists to make recommendations in Switzerland about when we should use anti-amyloid monoclonal antibodies in the care of patients with Alzheimer’s disease.
Although the article offers a land-specific framework for the use of MABS in clinical routine, the authors hope that if Alzheimer’s disease enters a new therapeutic era, these guidelines can balance innovation with clinical responsibility to determine a model for other nations that nations navigate similar questions.
It’s great that the diary Neurodegenerative diseases Serves as a home for such important guidance that has potential to influence thousands of patients, “
Professor Gilles Allali, editor -in -chief of Neurodegenerative diseases, Karger Publishers
“The latest guidelines from Swiss experts really have the potential to transform Alzheimer’s disease around the world.”